Defining the HTA landscape for France and Germany: 2019–2023
Health technology assessments (HTA), defined by the World Health Organization (WHO) as “the systematic evaluation of properties, effects and/or impacts…
Health technology assessments (HTA), defined by the World Health Organization (WHO) as “the systematic evaluation of properties, effects and/or impacts…
Recently, a study published in the National Library of Medicine compared market access trends in Belgium, France, Hungary, Italy, Switzerland,…
Recently back from the beautiful city of Copenhagen, it was an honour to see some of the brightest minds in…
The US is known for having higher list prices for drugs than other high-income countries. But these higher prices have…
Health technology assessments (HTA) are a formalized process for evaluating the value of a given health intervention. The outcomes of…
Lebanon’s ongoing economic crisis and changes in pricing strategies have caused monumental price hikes that impact market access. In Lebanon,…
As of 1 April 2023, Japan’s latest ‘off-year’ National Health Insurance (NHI) drug price revisions for FY2023 have now come…
Lebanon’s ongoing economic crisis and changes in pricing strategies have caused monumental price hikes that impact market access. In Lebanon,…
On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for haemophilia B, with…
France’s temporary authorisation system (autorisation temporaire d’utilisation, ATU) was developed to provide early market access for treatments in therapeutic areas…